3 Key Questions As Biosimilar Naming Fight Rages On
Drugmakers, pharmacists and insurance plans are wrangling in newly released letters to shape the U.S. Food and Drug Administration's recent proposals for assigning identical or distinct names to branded biologics and...To view the full article, register now.
Already a subscriber? Click here to view full article